Yan Leyfman: Do Pulmonary Function Tests Predict CAR-T Outcomes?
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn:
“Do Pulmonary Function Tests (PFTs) Predict CAR-T Outcomes?
PFTs are routinely used before hematopoietic cell transplantation (HCT), but their role in CAR-T therapy is less understood.
In a single-center study of 192 patients with relapsed/refractory B-cell lymphoma receiving CD19 CAR-T, researchers assessed whether FEV1, DLCO, and HCT-CI–based pulmonary comorbidity scores could predict outcomes and toxicity.
Key Findings:
Pulmonary comorbidity measures did not correlate with response rates or severe toxicities (CRS, ICANS).
Categorical FEV1, DLCO, and pulmonary comorbidity levels were not predictive of overall survival (OS) or progression-free survival (PFS).
- However, FEV1 as a continuous variable was significantly associated with PFS (HR 0.87; P = .007), suggesting better lung function = better PFS.
- Spline modeling confirmed a linear relationship between FEV1 and PFS.
These findings may help refine pre-CAR-T assessments and highlight the nuanced role of lung function in treatment outcomes.”
Authors: Inbal Sdayoor et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023